{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:36:47Z","timestamp":1769708207682,"version":"3.49.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since 2022, several biologics are indicated and reimbursed for Belgian patients with severe uncontrolled CRSwNP despite previous endoscopic sinus surgery (ESS). Data on the impact of biologics on the number of patients undergoing revision ESS are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the trend in numbers and percentages of patients with severe uncontrolled CRSwNP being offered primary ESS, revision ESS or biologics according to both academic- and reimbursement criteria at a tertiary care Rhinology center (University Hospitals Leuven) in Belgium, from 2019 until 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 641 patients with severe uncontrolled CRSwNP had been offered primary\/revision ESS or biologics in the past 5 years. In contrast to the overall increase in annual numbers of CRSwNP patients treated for uncontrolled CRSwNP from 2019 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009128) until 2023 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009160) by ESS or biologics, the absolute number of patients undergoing revision surgery is reduced by the advent of biologics since 2022. Patient numbers undergoing revision ESS were 66 and 59 in 2019 and 2020 respectively, and 48 in 2023. Moreover, the percentage of patients undergoing revision surgery dropped from 52% and 56% in 2019 and 2020, respectively to 34% and 30% in 2022 and 2023, respectively. The percentage of primary ESS procedures remained stable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The advent of biologics reduced the number and percentage of severe uncontrolled CRSwNP patients undergoing revision ESS, in contrast to number and percentage of primary ESS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2025.1725159","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:40Z","timestamp":1769668900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of biologicals on revision ESS numbers in CRSwNP in a tertiary care rhinology center"],"prefix":"10.3389","volume":"6","author":[{"given":"Judith E.","family":"Adriaenssens","sequence":"first","affiliation":[{"name":"Faculty of Medicine, KULeuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Sofie","family":"Viskens","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology & Head and Neck Surgery, UZA","place":["Antwerp, Belgium"]},{"name":"Laboratory of Allergy and Clinical Immunology, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elien","family":"Borgers","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology & Head and Neck Surgery, UZ Leuven","place":["Leuven, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[{"name":"Laboratory of Allergy and Clinical Immunology, KU Leuven","place":["Leuven, Belgium"]},{"name":"Department of Otorhinolaryngology & Head and Neck Surgery, UZ Leuven","place":["Leuven, Belgium"]},{"name":"Upper Airways Research Laboratory, University of Ghent","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-020-00218-1","article-title":"Adult chronic rhinosinusitis","volume":"6","author":"Bachert","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1356298","DOI":"10.3389\/fimmu.2024.1356298","article-title":"The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps","volume":"15","author":"Bachert","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.24401","article-title":"Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis","volume":"124","author":"Krings","year":"2014","journal-title":"Laryngoscope"},{"key":"B6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/19458924251315434","article-title":"Complication rates following endoscopic Sinus surgery for chronic sinusitis","volume":"39","author":"Dhamija","year":"2025","journal-title":"Am J Rhinol Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/all.12983","article-title":"Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre","volume":"72","author":"van der Veen","year":"2017","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4193\/Rhin19.184","article-title":"Long-term outcomes of different endoscopic sinus surgery in recurrent chronic rhinosinusitis with nasal polyps and asthma","volume":"58","author":"Zhang","year":"2020","journal-title":"Rhinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"B10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/alr.22487","article-title":"Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors","volume":"10","author":"Loftus","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4193\/Rhin20.570","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e12354","DOI":"10.1002\/clt2.12354","article-title":"Comorbidities of chronic rhinosinusitis in children and adults","volume":"14","author":"Murtom\u00e4ki","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12932\/AP-310321-1102","article-title":"Eosinophilia, asthma, NERD and the use of oral corticosteroids predict uncontrolled chronic rhinosinusitis with nasal polyps after surgery","volume":"42","author":"Penttil\u00e4","year":"2024","journal-title":"Asian Pac J Allergy Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1725159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:41Z","timestamp":1769668901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1725159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":20,"alternative-id":["10.3389\/falgy.2025.1725159"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1725159","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1725159"}}